| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/25/2006 | US20060110332 Agent for medicamentous treatment of acute and chronic pain |
| 05/25/2006 | US20060110331 Compositions comprising azelastine and methods of use thereof |
| 05/25/2006 | US20060110330 Inhalable pharmaceutical compositions containing an anticholinergic, formoterol, and a steroid |
| 05/25/2006 | US20060110329 Inhalable pharmaceutical compositions containing an anticholinergic, salmeterol, and a steroid |
| 05/25/2006 | US20060110328 Method of delivering nasal spray |
| 05/25/2006 | US20060110325 Serotonin and catecholamine segment optimization technology |
| 05/24/2006 | EP1659176A1 Oligonucleotide inhibiting the expression of star-binding protein (sbp) gene and method therefor |
| 05/24/2006 | EP1659172A1 Adipogenic differentiation of human mesenchymal stem cells |
| 05/24/2006 | EP1659125A1 Triptolide analogs for the treatment of autoimmune and inflammatory disorders |
| 05/24/2006 | EP1659121A1 1,3-dihydro-2h-indol-2-one derivative |
| 05/24/2006 | EP1659120A1 3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists |
| 05/24/2006 | EP1659117A1 2-naphthylimino-1,3-thiazine derivative |
| 05/24/2006 | EP1659116A1 Fki-1366 substances and process for producing the same |
| 05/24/2006 | EP1659115A1 Synthesis of substituted 2H-indazole derivatives as anti-angiogenic agents |
| 05/24/2006 | EP1659114A2 Process for the preparation of bicyclo[3.2.1]octane fused with quinazoline derivatives |
| 05/24/2006 | EP1659113A1 Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1) |
| 05/24/2006 | EP1659112A1 Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor |
| 05/24/2006 | EP1659111A2 Piperidine derivatives useful as ccr5 antagonists |
| 05/24/2006 | EP1659110A1 Process for the production of atorvastatin calcium un amorphous form |
| 05/24/2006 | EP1658881A1 Compositions for metabolic protection and repair of lips |
| 05/24/2006 | EP1658860A1 Drug compositions comprising anticholinergics and EGFR kinase inhibitors |
| 05/24/2006 | EP1658859A1 APO-2L receptor agonist and CPT-11 synergism |
| 05/24/2006 | EP1658858A2 Use of botulinum toxin for the treatment of unstable bladder |
| 05/24/2006 | EP1658854A2 Formulations useful in the treatment of male and female impotence |
| 05/24/2006 | EP1658852A1 Oral pharmaceutical preparation containing ibandronat |
| 05/24/2006 | EP1658851A1 Anti-asthmatic combinations comprising surface active phospholipids |
| 05/24/2006 | EP1658850A1 The use of mirtazapine for the treatment of sleep disorders |
| 05/24/2006 | EP1658849A2 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 05/24/2006 | EP1658848A1 Formulations comprising ecteinascidin and a disaccharide |
| 05/24/2006 | EP1658847A2 Indane derivatives as dermal anesthetic agents |
| 05/24/2006 | EP1658846A1 Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
| 05/24/2006 | EP1658845A1 Use of statin or precursor thereof for the treatment of virusinfections |
| 05/24/2006 | EP1658844A1 Use of artemisinin derivatives in the manufacture of a medicament for the treatment of melanoma |
| 05/24/2006 | EP1658843A1 Use of long chain alcohols for the treatment of hypercholesterolaemia |
| 05/24/2006 | EP1658306A1 Delta 15 -d-homosteroids having an androgenic effect |
| 05/24/2006 | EP1658302A2 Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c |
| 05/24/2006 | EP1658301A2 N-desmethyl-n-substituted-11-deoxyerythromycin compounds |
| 05/24/2006 | EP1658292A1 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| 05/24/2006 | EP1658291A2 Substituted 8-heteroaryl xanthines |
| 05/24/2006 | EP1658290A2 Compounds and compositions as protein kinase inhibitors |
| 05/24/2006 | EP1658289A2 3-substituted imidazopyridine-derivatives as c-kit inhibitors |
| 05/24/2006 | EP1658284A1 3,5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| 05/24/2006 | EP1658283A2 Substituted pyrrole derivatives and their use as hmg-co inhibitors |
| 05/24/2006 | EP1658277A1 Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament |
| 05/24/2006 | EP1658275A1 Crystalline form iv of linezolid |
| 05/24/2006 | EP1658274A2 Inhibitors of cathepsin s |
| 05/24/2006 | EP1658267A2 Inhibitors of cathepsin s |
| 05/24/2006 | EP1658255A2 Proteasome inhibitors and methods of using the same |
| 05/24/2006 | EP1658098A1 Pharmaceutical composition comprising an alpha2delta ligand and an opioid receptor antagonist for the prevention and treatment of addiction in a mammal |
| 05/24/2006 | EP1658096A1 Method of inducing immune tolerance |
| 05/24/2006 | EP1658093A2 Use of a mixture containing neuropeptides and steroids for treating disturbances of psychosocial experiences and behaviour |
| 05/24/2006 | EP1658092A1 A method for treating cancer patients undergoing chemotherapy |
| 05/24/2006 | EP1658089A2 Compositions for treating pathologies that necessitate suppression of gastric acid secretion |
| 05/24/2006 | EP1658086A2 Liposomes containing phosphate glycerol groups for treating acute inflammatory condition |
| 05/24/2006 | EP1658085A1 Use of bisphosphonates for otosclerosis |
| 05/24/2006 | EP1658084A2 Compositions comprising zd6126 together with 5-fu, cpt-11 or 5-fu and cpt-11 having vascular damaging activity for treating e.g. colorectal cancer |
| 05/24/2006 | EP1658083A1 Enhancement of activity and/or duration of action of selected anti-inflammatory steroids |
| 05/24/2006 | EP1658082A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| 05/24/2006 | EP1658081A2 Immunosuppressive effects of pteridine derivatives |
| 05/24/2006 | EP1658080A1 Dosing schedule for a erbb2 anticancer agents |
| 05/24/2006 | EP1658079A1 Multivitamin syrup for children or young adults |
| 05/24/2006 | EP1658078A2 Methods for intradermal delivery of therapeutics agents |
| 05/24/2006 | EP1658077A2 Dual function compounds and uses thereof |
| 05/24/2006 | EP1658076A1 Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
| 05/24/2006 | EP1658075A2 Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis |
| 05/24/2006 | EP1658074A1 Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| 05/24/2006 | EP1658073A1 Pharmaceutical product for injection |
| 05/24/2006 | EP1658071A2 Cyanoguanidine-based azole compounds useful as malonyl-coa decarboxylase inhibitors |
| 05/24/2006 | EP1658070A2 Use of antifungal agents for treating otitis externa |
| 05/24/2006 | EP1658068A1 Novel cycloalkyl'b! condensed indoles |
| 05/24/2006 | EP1658065A2 Using selective antagonists of persistent sodium current to treat neurological disorders and pain |
| 05/24/2006 | EP1658064A2 Combinations of vasoactive agents, their use in the pharmaceutical and cosmetic field, and formulations containing them |
| 05/24/2006 | EP1658063A1 Advantageous combinations for inhalation of nacystelyn and bronchodilators |
| 05/24/2006 | EP1658062A1 Alpha-aminoamide derivatives useful as anti-inflammatory agents |
| 05/24/2006 | EP1658061A2 Aerosol delivery of curcumin |
| 05/24/2006 | EP1658060A2 Methods of treating copd and pulmonary hypertension |
| 05/24/2006 | EP1658059A1 A pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
| 05/24/2006 | EP1658058A1 A pharmaceutical composition for the prevention and treatment of addiction in a mammal |
| 05/24/2006 | EP1658056A1 Tablet containing 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]- methyl}-1-methyl-1h-benzimidazolo-5-carbonyl)-pyridino-2-yl- amino]-ethyl propionate or the salts thereof |
| 05/24/2006 | EP1658055A1 Form of administration secured against misuse |
| 05/24/2006 | EP1658054A1 Dosage form that is safeguarded from abuse |
| 05/24/2006 | EP1658053A2 Novel compositions of sildenafil free base |
| 05/24/2006 | EP1658050A1 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs |
| 05/24/2006 | EP1658049A2 Ferromagnetic particles and methods |
| 05/24/2006 | EP1658048A2 Stepwise delivery of topiramate over prolonged period of time |
| 05/24/2006 | EP1658039A2 Use of biotin or a biotin derivative for lightening skin and treating age spots |
| 05/24/2006 | EP1658035A2 Delivery of immune response modifier compounds |
| 05/24/2006 | EP1658034A2 Antibiotic product, use and formulation thereof |
| 05/24/2006 | EP1658029A1 Transdermal hormone delivery system: compositions and methods |
| 05/24/2006 | EP1657978A2 Antimicrobial acrylic polymer |
| 05/24/2006 | EP1605932B1 Intranasal formulation of rotigotine |
| 05/24/2006 | EP1585513B1 Use of docosahexanoic acid as active substance for the treatment of lipodystrophy |
| 05/24/2006 | EP1565176B1 Agent having a destructive effect on malignant tumors and method for the production thereof |
| 05/24/2006 | EP1553942B1 Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent |
| 05/24/2006 | EP1551850B1 2" oxo-voruscharin and derivatives thereof |
| 05/24/2006 | EP1549639B1 Sulphonamide derivatives as antipsychotic agents |
| 05/24/2006 | EP1539723B1 Novel use of benzothiazole derivatives |
| 05/24/2006 | EP1529050B1 Cephalosporins |
| 05/24/2006 | EP1508333B1 Novel therapeutic use of riboside of 5-aminoimidazole-4- carboxamide (acadesine) |
| 05/24/2006 | EP1506185B1 Compounds and their use as inhibitors of 5-ht |